MELINA SIMS: Open Payments
NPI 1851096903 · SURPRISE, AZ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,154 in 64 payments from 14 companies in 2025. Trend: 2023 $0 · 2024 $1,170 · 2025 $2,154
Food & beverage: $2,154
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 14 | $792 |
| ABBVIE INC. | 16 | $433 |
| Astellas Pharma US Inc | 3 | $186 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 5 | $175 |
| Novo Nordisk Inc | 8 | $163 |
| Sumitomo Pharma America, Inc. | 4 | $99 |
| Corcept Therapeutics | 3 | $97 |
| Amgen Inc. | 4 | $60 |
| Aimmune Therapeutics, Inc. | 2 | $53 |
| Phathom Pharmaceuticals, Inc. | 1 | $22 |
Products named: BREZTRI, VRAYLAR, AIRSUPRA, Veozah, CAPLYTA, FARXIGA, GEMTESA, Korlym.
Industry payments across AZ — which companies pay providers there.
